Expert offers advice to practitioners about novel coronavirus 2019.
November 21st, 2026Takeaways from this week in optometry: November 16-20Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.Read more
November 20th, 2026Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health CanadaYuvezzi Health Canada submission builds on BRIO-I and BRIO-II phase 3 data.Read more
November 20th, 2026Polygenic risk flags patients likely to need more glaucoma treatment Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.Read more
November 19th, 2026First patient dosed in EMERALD trial of EO2002 for corneal edemaThe phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.Read more
November 19th, 2026High Point University optometry school earns ACOE preliminary approvalThe school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.Read more
November 18th, 2026Alice Epitropoulos, MD, on phentolamine for presbyopia treatmentThe FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.Read more
November 18th, 2026The Independent Advantage S02 E11: AI-powered front desks: Now and in the futureWill AI reinvent the way patients book appointments in the next 5 years? Raphael Rostenne weighs in in the season 2 finale of The Independent Advantage.Read more
November 17th, 2026Alberta expands optometry scope to include laser proceduresTrained Alberta optometrists may now perform SLT, peripheral iridotomy, and YAG capsulotomy in the office.Read more